{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T08:36:10Z","timestamp":1794731770592,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      CFTR-modulators are a category of drugs that facilitate trafficking and opening of the abnormal CFTR protein in individuals with cystic fibrosis (CF) who have certain genetic mutations. Clinical trial data show that individuals taking CFTR-modulators have increased or stable lung function (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) as well as reduced frequency of pulmonary exacerbations. There are no data on whether CFTR-modulators influence psychosocial aspects of the lives of individuals with CF. The purpose of this qualitative study was to explore how the introduction of CFTR-modulators has affected individuals\u2019 lived experiences outside of clinical health variables; that is, to explore whether there is a relationship between using CFTR-modulator drugs and the psychological and social aspects of the lives of individuals with CF, including: career, relationships, family planning and psychological functioning.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight men and women with CF ages 24\u201332, with a history of taking any approved CFTR-modulator for at least six months, were recruited from an adult CF center. A semi-structured interview guide was used to interview the participants. The data were coded using a grounded theory approach with an iterative methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four themes emerged from the data: stability, identity, potentiality, and hope.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although these themes cannot be generalized to all individuals with CF, this study provides preliminary data for how CFTR-modulators may influence an individual with CF\u2019s outlook on life and that these individuals are feeling hopeful about the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-022-01825-2","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:03:22Z","timestamp":1642741402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Lived experiences of individuals with cystic fibrosis on CFTR-modulators"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-6764","authenticated-orcid":false,"given":"Annelise","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"9678","key":"1825_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140","volume":"373","author":"BP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan BP, Freedman SD. Cystic fibrosis. The Lancet. 2009;373(9678):1891\u2013904. https:\/\/doi.org\/10.1016\/S0140.","journal-title":"The Lancet"},{"issue":"18","key":"1825_CR2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663\u201372. https:\/\/doi.org\/10.1056\/NEJMoa1105185.","journal-title":"N Engl J Med"},{"issue":"3","key":"1825_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, et al. Lumacaftor\u2013Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1409547.","journal-title":"N Engl J Med"},{"issue":"21","key":"1825_CR4","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar JL, et al. Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377(21):2013\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1709846.","journal-title":"N Engl J Med"},{"issue":"f","key":"1825_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10897-016-9978-1","volume":"26","author":"CR Elsas","year":"2017","unstructured":"Elsas CR, et al. Attitudes toward discussing approved and investigational treatments for cystic fibrosis in prenatal genetic counseling practice. J Genet Couns. 2017;26(f):63\u201371. https:\/\/doi.org\/10.1007\/s10897-016-9978-1.","journal-title":"J Genet Couns"},{"key":"1825_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s10897-012-9555-1","volume":"22","author":"L Higham","year":"2013","unstructured":"Higham L, et al. Hoping to live a \u2018normal\u2019 life whilst living with unpredictable health and fear of death: impact of cystic fibrosis on young adults. J Genet Counsel. 2013;22:374\u201383. https:\/\/doi.org\/10.1007\/s10897-012-9555-1.","journal-title":"J Genet Counsel"},{"issue":"5","key":"1825_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ppul.20090","volume":"38","author":"EJ Burker","year":"2004","unstructured":"Burker EJ, et al. Psychological and educational factors: better predictors of work status than FEV1 in adults with cystic fibrosis. Pediatr Pulmonol. 2004;38(5):413\u20138. https:\/\/doi.org\/10.1002\/ppul.20090.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"1825_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/occmed\/kqt140","volume":"64","author":"K Targett","year":"2014","unstructured":"Targett K, et al. Employment in adults with cystic fibrosis. Occup Med. 2014;64(2):87\u201394. https:\/\/doi.org\/10.1093\/occmed\/kqt140.","journal-title":"Occup Med"},{"issue":"2","key":"1825_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jcf.2011.10.008","volume":"11","author":"H Laborde-Cast\u00e9rot","year":"2012","unstructured":"Laborde-Cast\u00e9rot H, et al. Employment and work disability in adults with cystic fibrosis. J Cyst Fibros. 2012;11(2):137\u201343. https:\/\/doi.org\/10.1016\/j.jcf.2011.10.008.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1825_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jcf.2008.10.001","volume":"8","author":"T Besier","year":"2009","unstructured":"Besier T, et al. Life satisfaction of adolescents and adults with cystic fibrosis: impact of partnership and gender. J Cyst Fibros. 2009;8(2):104\u20139. https:\/\/doi.org\/10.1016\/j.jcf.2008.10.001.","journal-title":"J Cyst Fibros"},{"key":"1825_CR11","volume-title":"Cystic fibrosis and congenital absence of the vas deferens. GeneReviews\u00ae","author":"T Ong","year":"1993","unstructured":"Ong T, et al. Cystic fibrosis and congenital absence of the vas deferens. GeneReviews\u00ae. Seattle: University of Washington; 1993."},{"issue":"1","key":"1825_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1378\/chest.118.1.85","volume":"118","author":"M Gilljam","year":"2000","unstructured":"Gilljam M, et al. Pregnancy in cystic fibrosis: fetal and maternal outcome. Chest. 2000;118(1):85\u201391. https:\/\/doi.org\/10.1378\/chest.118.1.85.","journal-title":"Chest"},{"issue":"4","key":"1825_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.4187\/respcare.01328","volume":"57","author":"AM Yohannes","year":"2012","unstructured":"Yohannes AM, et al. Relationship between anxiety, depression, and quality of life in adult patients with cystic fibrosis. Respir Care. 2012;57(4):550\u20136. https:\/\/doi.org\/10.4187\/respcare.01328.","journal-title":"Respir Care"},{"key":"1825_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jcf.2014.04.005","volume":"13","author":"KN Oliver","year":"2014","unstructured":"Oliver KN, et al. Stigma and optimism in adolescents and young adults with cystic fibrosis. J Cyst Fibros. 2014;13:737\u201344. https:\/\/doi.org\/10.1016\/j.jcf.2014.04.005.","journal-title":"J Cyst Fibros"},{"key":"1825_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jcf.2008.05.010","volume":"7","author":"T Havermans","year":"2008","unstructured":"Havermans T, et al. Quality of life in patients with cystic fibrosis: association with anxiety and depression. J Cyst Fibros. 2008;7:581\u20134. https:\/\/doi.org\/10.1016\/j.jcf.2008.05.010.","journal-title":"J Cyst Fibros"},{"issue":"12","key":"1825_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","volume":"69","author":"AL Quittner","year":"2014","unstructured":"Quittner AL, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014;69(12):1090\u20137. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205983.","journal-title":"Thorax"},{"key":"1825_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lisr.2007.11.003","author":"K Charmaz","year":"2006","unstructured":"Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Book. 2006. https:\/\/doi.org\/10.1016\/j.lisr.2007.11.003.","journal-title":"Book"},{"issue":"2","key":"1825_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jcf.2005.02.004","volume":"4","author":"JE Szyndler","year":"2005","unstructured":"Szyndler JE, et al. Psychological and family functioning and quality of life in adolescents with cystic fibrosis. J Cyst Fibros. 2005;4(2):135\u201344. https:\/\/doi.org\/10.1016\/j.jcf.2005.02.004.","journal-title":"J Cyst Fibros"},{"issue":"9","key":"1825_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0277-9536(00)00416-0","volume":"53","author":"E Willis","year":"2001","unstructured":"Willis E, et al. Gendered embodiment and survival for young people with cystic fibrosis. Soc Sci Med. 2001;53(9):1163\u201374. https:\/\/doi.org\/10.1016\/S0277-9536(00)00416-0.","journal-title":"Soc Sci Med"},{"issue":"3","key":"1825_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.35680\/2372-0247.1200","volume":"4","author":"S Horky","year":"2017","unstructured":"Horky S, et al. I\u2019m going to tell you a little about myself: illness centrality, self-image and identity in cystic fibrosis. Patient Exp J. 2017;4(3):95\u2013103.","journal-title":"Patient Exp J"},{"key":"1825_CR21","doi-asserted-by":"publisher","first-page":"714","DOI":"10.5604\/17322693.1014657","volume":"66","author":"G Cepuch","year":"2012","unstructured":"Cepuch G, et al. Patient\u2019s perception of the meaning of life in cystic fibrosis\u2014its evaluation with respect to the stage of the disease and treatment. Post\u0119py Higieny Med Do\u015bw. 2012;66:714\u201321. https:\/\/doi.org\/10.5604\/17322693.1014657.","journal-title":"Post\u0119py Higieny Med Do\u015bw"},{"issue":"10212","key":"1825_CR22","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, et al. Efficacy and safety of the elexacaftor plus Tezacaftor plus Ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8.","journal-title":"Lancet"},{"issue":"2","key":"1825_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani C, et al. ECFS best practice guidelines\u202f: the 2018 revision. J Cyst Fibros. 2018;17(2):153\u201378. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006.","journal-title":"J Cyst Fibros"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01825-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:04:06Z","timestamp":1642741446000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01825-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01825-2","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University Hospitals Institutional Review Board, which operates under HHS Federalwide Assurance number 00003937. Written informed consent was obtained from the participants. All participants were able to provide full informed consent themselves, as all participants are legal adults over the age of 18.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}